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Abstract

Introduction

Carboplatin (diammine [1,1 cyclobutane dicarboxylato
(2)-0,0'] platinum) is an anti-cancer agent which can be
toxic to the inner ear. We have explored the nature of this
ototoxicity in the chinchilla.
In this species, initial
degenerative changes appear to be restricted to the inner
hair cell (IHC) regions of the organ of Corti. This finding
is intriguing and unusual since all other known ototoxic
drugs, such as aminoglycosides, are predominantly associated with outer hair cell damage.
In the present study, the mechanism of ototoxicitywas
investigated by comparing two different routes of carboplatin administration. Carboplatin was administered either
intravenously (i. v .) or intraperitoneally (i.p.). The mode
of administration influenced electrophysiological and morphological changes. Hearing thresholds were elevated in
the i.v. group significantly more than in the i.p. group at
all tested frequencies. The degree of hair cell damage was
evaluated by scanning electron microscopy at four frequency regions in each cochlea. IHC damage in the i. v.
group was significantly more severe than in the i.p. group.
Carboplatin effects on a different species, the guinea
pig, were also determined to clarify interspecies differences. In the guinea pig, outer hair cell damage occurred
sporadically and inner hair cells remained intact. In contrast, chinchilla inner hair cells are susceptible to the
ototoxic effects of carboplatin. The degree of hair cell
damage appears to be dependent on the peak level of carboplatin rather than on the total dose. This animal model
provides a new tool for the investigation of inner and outer
hair cell function.

The development of the platinum group of anti-cancer
drugs originated in 1965 with pioneering work in which the
inhibitory effects of soluble platinum salts on cP!! ~i vi~ion
of Escherichia coli were discovered (Rosenberg et al.,
1965, 1969). Cisplatin was the first and the most potent
drug from the platinum group and has been used for over
a decade for the treatment of various cancers. However,
cisplatin has serious dose-limiting side effects of nephrotoxicity and neurotoxicity. Ototoxicity, in the form of
dose-dependent sensorineural hearing loss, is another major
side effect of cisplatin treatment. In an attempt to reduce
the dose-limiting toxicities, a second generation of platinum
compounds was developed and entered clinical trials.
Carboplatin (diammine [1, 1 cyclobutane dicarboxylato
(2)-0,0'] platinum, CBDCA) is one of the cisplatin analogues. Carboplatin expresses its anti-neoplastic effect by
forming inter/intra-strand DNA cross-links when converted
into a hydrated species (van Hennik et al., 1987). In clinical experience, carboplatin causes significant, dose-limiting,
myelosuppression but is reported to be less nephrotoxic and
ototoxic than cisplatin. The incidence of hearing loss in
humans caused by carboplatin, generally restricted to the
higher frequencies, ranges from Oto 19% (Calvert et al.,
1982;Kennedyeta/.,
1990;Macdonaldetal.,
1994). This
value is less than that of cisplatin which ranges from 25 to
100% (Lippman et al., 1973; Piel et al., 1974; Strauss et
al., 1983; Kopelman et al., 1988; Myers et al., 1991).
The large variability in reported incidence of ototoxicity is
influenced by: mode of administration, cumulative total
dosage and maximal single dosage, age of patient, and presence or absence of a preexisting hearing defect. In experimental animal models, ototoxic effects of these two platinum compounds on the organ of Corti have been characterized by a range of outer hair cell (OHC) damage across
various species including guinea pigs (Estrem et al., 1981;
Nakai et al., 1982; Tange et al., 1982; Schweitzer et al.,
1984, 1986; Marco-Algarraet al., 1985; Saito et al., 1989;
McAlpine and Johnstone, 1990; Tautly et al., 1992), monkeys (Stadnicki et al., 1975), and rats (Anzai et al, 1987).
The ototoxic potential has also been analyzed using organ
culture models (Ann.iko and Sobin, 1990). All these data
have consistently indicated that the predominant effect of
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both compounds is OHC degeneration, carboplatin being
less ototoxic than cisplatin.
We have recently found that in chinchillas carboplatin
is highly ototoxic (Wake et al., 1993; Takeno et al., 1994).
A single intravenous administration of 200 to 400 mg/m 2
carboplatin, which is equivalent to the clinically suggested
therapeutic dose, is enough to induce significant hearing
threshold elevation as determined by auditory brainstem
evoked responses (ABR). Furthermore, the degenerative
changes seen in the organ of Corti are highly selective to
the inner hair cells (IHCs). An IHC lesion is very unusual
since all known cochleotoxic drugs in any other animal
model predominantly and initially affect OHCs. While IHC
loss due to cisplatin ototoxicity has been observed both in
humans (Wright and Schaefer, 1982; Strauss et al., 1983)
and in rhesus monkeys (Stadnicki et al., 1975), it always
occurred subsequent to extensive OHC damage. To the
best of our knowledge, the only combination producing a
lesion with missing IHCs and intact OHCs is carboplatin in
chinchillas.
In the present study, we describe detailed morphological features of this intriguing animal model using scanning
electron microscopy (SEM). The results are compared with
physiological data obtained by ABR recordings. In the
chinchilla, two different routes of administration of carboplatin (intravenous: i.v.; and intraperitoneal: i.p.) were
employed to determine potential differences in ototoxic effects. In an additional study, guinea pigs were treated with
the same dosage of carboplatin to clarify the unique interspecies difference between chinchillas and other animals.

RW

(J
ow
Figure 1. Frequency position map of the chinchilla cochlea. Characteristic frequencies are assigned along the
cochlea length according to the data of Eldredge et al.
(1981). Note that 8, 4, 2 kHz regions are located in the
basal turn, and 1, 0.5 kHz regions are included in the
second turn. RW: round window. OW: oval window.
Sound stimuli were tone pips (2 ms rise/fall, 2 ms plateau)
at octave intervals between 0.5 and 8 kHz. These signals
were calibrated in an artificial (chinchilla) ear using a
standard reference. Sound was delivered free-field in a
sound attenuated room. Potentials were band pass filtered
(150 Hz - 3 kHz) and amplified conventionally. After analogue to digital conversion and artifact rejection, signals
were averaged over 300 sweeps in a 25 ms window (Cambridge Electronic Design 1401 intelligent interface with
80286 microprocessor host). ABR waveform amplitudes
were measured over a range of stimulus intensities allowing
threshold determinations. Bilateral pre- and post-treatment
ABR audiograms were determined for each animal.
All animals were prepared for morphological evaluation of the cochleas immediately following the final recording sessions. Under deep anesthesia with sodium pentobarbital (50 mg/kg), cardiac perfusion was carried out with
fixative (1.25 % glutaraldehyde, 1 % paraformaldehyde in
0.1 M phosphate buffer, pH 7.4), and the temporal bony
capsules were removed. Cochleas were exposed and perfused with 2.5 % glutaraldehyde in 0.1 M phosphate buffer
through the oval and round windows. The specimens were
then prepared for SEM. After initial fixation, the specimens were rinsed in 0.1 M phosphate buffer and conductive
stained with 1% tannic acid for 30 minutes followed by
post-fixation with 0.5 % osmium tetroxide for 15 minutes.
After dehydration through a graded ethanol series (50, 70,
80, 90, 95 and 100% twice), specimens were immersed in

Materials and Methods
Adult chinchillas and albino (Hartley) guinea pigs, free
from ear disease, were used in this study. Three treatment
groups were set up as follows: A) 6 chinchillas treated with
carboplatin injected into the internal jugular vein (i. v .); B)
6 chinchillas treated with i.p. injection of carboplatin; and
C) 6 albino guinea pigs treated with i.p. injection of
carboplatin. In all groups, carboplatin in 5 % dextrose was
administered as a single injection at the dose of 400 mg/m 2
(total volume 3 ml). This is equivalent to the maximum
therapeutic dose clinically scheduled for single-agent
regimens as a single i. v. injection. Additionally, two
control studies were carried out: D) chinchillas identically
treated with 3 ml i.v. injection of 5% dextrose without
carboplatin; and E) guinea pigs treated with 3 ml i.p.
injection of 5 % dextrose without carboplatin.
Carboplatin for the study was supplied by Bristol
Myers Canada (Paraplatin-AQ). The surface area of the
animals was estimated using the formula of Yates and
Kugler (1986). ABR recordings of all animals were carried
out prior to and two weeks after treatment.
ABR recordings were obtained from animals lightly
anesthetized using ketamine (15 mg/kg), xylazine (2.5
mg/kg) and atropine (0.004 mg/kg). Skin needle electrodes
were used in a standard vertex to post-aural configuration.
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Figure 2. ABR threshold elevation values (mean ± standard deviation, S.D.) after carboplatin treatment for experimental groups A, B, and C (10 cochleas in each group).
a) Group A (i.v. in the chinchilla) shows the most remarkable changes at all frequencies. b) Group B (i.p. in the
chinchilla) shows less hearing loss compared to Group A.
c) Group C (i.p. in the guinea pig) developed only minimal
changes in threshold elevation.
Statistical differences
observed in the chinchilla between group A (i. v .) and group
B (i.p.) are indicated by: * (p < 0.05), ** (p < 0.01);
(two-sample t-test).
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Care Committees and following national guidelines issued
by the Canadian Council on Animal Care, as well as local
(Ontario) legislation.

Results
The single administration of 400 mg/m 2 carboplatin
caused the death of one subject in each group due to acute
toxicity. The necropsy data suggested the existence of
severe pulmonary infection triggered by myelosuppression.
Therefore, 10 cochleas in total (5 animals) from each group
were assessed for ABR threshold elevation and hair cell
condition. The general condition of the surviving carboplatin treated animals was good throughout the experiments.
They appeared healthy with normal behavior.

amyl acetate for 30 minutes then critical point dried from
CO2 . Specimens were sputter coated with 30 A thick gold.
The extent of IHC and OHC damage observed by SEM
was assessed in specific regions of the cochlea and compared to the corresponding ABR data. In the chinchilla,
cochlear frequency-place maps derived by Eldredge et al.
(1981) were used. Hair cell damage was assessed in the
0.5, 1, 2, 4 and 8 kHz regions (Fig. 1). In the guinea pig,
the mid-portion of each turn of the cochlea was observed as
described elsewhere (Saito et al., 1989). At each assessed
location, an area of the organ of Corti containing 100 IHCs
and 100 each first, second and third row OHCs was examined to determine the degree of damage in each of the four
rows. Hair cell condition was graded using the following
criteria: Grade O = normal to slight damage (less than 20 %
disruption of the stereocilia); Grade 1 = moderate damage
(disruption of stereocilia but with less than 50% of stereocilia missing); Grade 2 = severe damage (less than 50%
surviving stereocilia); and Grade 3 = presence of fusion/
extrusion bodies, or total loss of stereocilia or hair cell (this
grading scheme was modified from that of Fukushima et
al., 1990). Final hair cell damage scores are calculated
according to the formula below and expressed as a percentage (total loss = 100%).

ABR threshold shifts
In Figure 2, the mean values (± 1 S.D.) of post-treatment ABR threshold elevations (i.e., the difference between
the pre- and post-treatment threshold level in each subject)
are plotted for the three experimental groups. The majority
of cochleas from each group showed differences in pre- and
post-treatment thresholds. Group C (i.p. injection in the
guinea pig; right-hand plot) developed only minimal
changes in hearing sensitivity with the administration of 400
mgtm 2 carboplatin. In this group, less than 10 dB threshold elevation was found across the tested frequencies. In
group B (i.p. injection in the chinchilla; center plot), the
mean threshold elevation ranged from 7.5 dB to 15.5 dB,
the greater shifts occurred at higher frequencies.
The most significant threshold elevations occurred in
group A (i. v. injection of carboplatin in the chinchilla, lefthand plot). In this group, seven of ten cochleas sustained
severe hearing loss (more than 40 dB) including unrecordable potentials especially at high frequencies.
A large
inter-individual variability was also noted in this group as
indicated by the standard deviation bars. Similar to group
B, hearing losses are greater at higher frequencies.
Threshold elevations at all frequencies of group A were
significantly greater (p < 0.01 at 0.5, 1, 4 and 8 kHz;
0.01 < p < 0.05 at 2 kHz; two-sample t-test) than group
B. Differences in threshold shifts (averaged of all frequencies) between the right and the left cochleas were also

(total grade number)
x
100
(number of evaluated hair cells) x 3
All procedures using animals were carried out with
strict adherence to standards implemented by local Animal
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observed in some subjects. Thus, 4 of 5 in group A, 2 of
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dB disparity between sides when averaged across frequencies.
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After ABR measurements were obtained, all cochleas
were examined by SEM to assess the relationship between
physiological and morphological findings. The most remarkable difference in morphological abnormalities between
the two different species (chinchillas and guinea pigs)
following carboplatin treatment was in the type of damage
to the organ of Corti. In the chinchilla (groups A and B),
the IHC region was predominantly affected, with OHCs being damaged to a lesser degree. On the contrary, in the
guinea pig (group C), IHCs remained intact in all subjects,
and only mild sporadic degeneration was observed in the
OHC area. In Figure 3, the degrees of damage suffered by
IHCs and OHCs are summarized for four frequency regions
in the chinchilla and at three turns in the guinea pig. Figures 4, 5, and 6 are scanning electron micro graphs showing

~

I

80

3rd turn

100 '------'------'

IHC

OHC

c) Group C

Figure 3. Relative proportion of inner and outer hair cell damage (mean± S.D.) at each sampled location for experimental groups A, B, and C; (IO cochleas in each group). a) Group A
(i. v. in the chinchilla) shows the most extensive destruction of sensory epithelium both in inner
and outer hair cell regions. b) Group B (i.p. in the chinchilla) also shows similar patterns of
hair cell damage to those of group A, but the degree of IHC damage is much lower. c) Group
C (i.p. in the guinea pig) developed only minimal cytoarchitectural changes in the hair cells.
The changes observed in the two chinchilla groups of different drug administration routes
(groups A and B) are significantly different: * (p < 0.05); ** (p < 0.01); (two-sample t-test).
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Scanning electron photomicrographs of the

Figure 5. Scanning electron photomicrographs showing

organ of Corti showing representative samples from group

representative samples from group B. (a) The gross view
of the 4 kHz region in this subject demonstrates a Joss of
> 50% IHCs with a normal OHC population. In general,
i.p. injection of carboplatin induced milder damage to the
hair cells than i.v. injection. Furthermore, formation of
fusion/extrusion bodies, which occasionally occurred subsequent to IHC degeneration in i.v. cases, is not commonly
detected in i.p. cases (IHC loss: 67%; OHC Joss: 0.6%).
(b) In this 2 kHz region of group B, moderately preserved
IHCs are demonstrated (IHC loss: 33 %; OHC Joss: 0.8%).

Figure 4.

A. (a) In this 8 kHz region, i. v. injection of carboplatin
caused almost total IHC destruction. Characteristic formation of fusion/extrusion bodies is demonstrated on the surface of reticular lamina. The OHCs remain intact in this
area (IHC loss; 97%, OHC loss; 10%). (b) Two of ten
cochleas in group A showed considerable OHC degeneration along with complete IHC loss. This relatively rare
case is demonstrated in the 4 kHz region (IHC loss: 94 %;
OHC Joss: 30%).
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Figure 6. Scanning electron micrographs showing representative samples from group C. (a) The most intriguing finding here
is that carboplatin induces no IBC damage in the guinea pig in complete contrast to the chinchilla. This micrograph from the
3rd turn of a guinea pig's cochlea demonstrates an intact row of IBCs with occasionally missing OHCs (IHC loss: 1 % ; OHC
loss: 2 %). (b) Mildly scattered loss of OH Cs is observed in the I st turn region of this specimen (IHC loss: 0 %; OHC loss:
4%).
representative samples of the damaged sensory epithelium
from treatment groups A, B, and C respectively.
Inner hair cell damage was greatest in group A animals
at all frequency locations. Mean values of group A damage
scores ranged from 50% at 1 kHz to 76% at the 8 kHz region. A general finding of carboplatin ototoxicity in the
chinchilla (both i. v. and i.p. treated subjects) was that more
IBC damage was noted in the higher frequency regions than
in the apical lower frequency areas. Group A animals have
a high degree of variability of inter-cochlea susceptibility to
IBC damage (Fig. 3a), as is also reflected in the variability
in ABR threshold shifts (Fig. 2a). In group B, the pattern
of hair cell damage caused by carboplatin was similar to
that of group A in all four frequency areas. However, the
degree of IBC damage was less (from 22 % damage at 1
kHz to 46% at the 8 kHz region) than that of group A, and
the variability between cochleas was reduced particularly in
the lower frequencies. OHC damage in this group was
minimal with generally less than 2 % OHC damage observed across all frequencies. The degree of IBC and OHC
degeneration assessed at four frequency regions was statistically different from those of group A (p < 0.01 at 1, 2,
4, 8 kHz for IHCs and at 8 kHz for OHCs; 0.01 < p <
0.05 at 1, 2, 4 kHz for OHCs; two sample t-test). The
guinea pigs of group C did not show significant cytoarchitectural changes in the sensory epithelium except for some
occasional scattered loss of OHCs. In general, there was
less than 5 % OHC damage and almost no IHC damage in
this group.

Figure 7 summarizes the distributions of the surviving
three rows of OHCs in each group. In general, carboplatin
toxicity results in only minimal damage to OHCs of the
three rows in groups B and C. In group A, two of ten
cochleas indicate significant OHC loss (20-30% OHC damage), which is dominant toward the basal region and more
pronounced in the first row. IHCs of these subjects are
more extensively damaged (70-90% damage) than others in
the group. Results of the statistical analysis (ANOVA; single factor) revealed no significant difference in damage to
OHCs among the three rows either at any frequency region
or at any turn in the three groups.
The control studies in both species gave the following
results: normal animals treated with 5 % dextrose, either
i. v. (chinchillas) or i.p. (guinea pigs), showed no audiometric threshold elevation and retained morphologically
normal cochleas.

Discussion
Comparison of drug administration routes

In the present study, two different routes of administration of carboplatin were employed in the chinchilla, and
the resulting physiological and morphological changes were
analyzed statistically. The mode of administration of platinum compounds has been previously investigated by others
with respect to both the therapeutic index in treating disease
and systemic toxicity, especially nephrotoxicity, bone marrow suppression and ototoxicity.
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80
while the others maintain well-preserved OHCs. b) Group B (i.p. in the chinchilla) shows alOHC1 OHC2 OHC3 most intact OHCs in all subjects. c) In group C (i.p. in the guinea pig), despite totally intact
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Figure 6. In all three groups, no significant increase in damage to OHCs of any particular row
c) Group C
is detected at the locations demonstrated here (ANOVA; single factor).
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platinum level measured in mice was nearly 7-fold higher
than in humans, but the initial half-time was 6 times shorter
in mice. In the present study, we did not measure actual
levels of carboplatin with respect to serum and inner ear
tissues. However, based on the above mentioned studies,
we expect the peak serum level to be significantly higher in
the i.v. injected group than in the i.p. injected group.
The route of administration (i.v. versus i.p.) does not
affect systemic toxicity with reference to renal and bone
marrow functions in dogs treated with a relatively high
dose (3 mg/kg) of cisplatin for that species (Pretorius et
al., 1981). However, regarding ototoxicity, Laurell and
Engstrom (1989) reported different effects of cisplatin
between a single high-dose i.v. injection and multiple lowdose i.p. injections in guinea pigs. With i. v. injection, the
loss of endocochlearpotentials (EP) was detected as well as
ABR threshold elevation, while no permanent change in EP
was seen with multiple low-dose treatment despite the
occurrence of a more profound hearing loss. Our present
study aiso showed significant difference in carboplatin ototoxicity, both physiologically and morphologically, between
the two administration routes. ABR threshold elevation in
chinchillas induced by i. v. carboplatin was greater than that
by i.p. injections at all measured frequencies.
Consistent with degree of auditory threshold elevation,
we observed that pathological changes to the organ of Corti
differ in degree of damage to the hair cells between the i. v.
and i.p. treated groups. We might conclude that the significant differences in ABR threshold elevations primarily
reflect degenerative changes occurring in the IHC regions.
However, after administration of 400 mg/m 2 i. v. carboplatin in chinchillas, in addition to the total loss of IHCs,
degenerative changes were occasionally seen in the stria
vascularis. The observed pathology included gross capillary dilatation, widening of intercellular spaces and marginal cell flattening (Wake et al., 1993). Marginal cells of
the stria vascularis have also been documented as a target
of platinum compounds by others (Tange and Vuzevski,
1984; Kohn et al., 1988, 1991). In relation to stria! damage, Konishi et al. (1983) reported a decrease in the endocochlear potential and suppression of the cochlear microphonic in cisplatin treated guinea pigs. The stria vascularis
seems to be less susceptible than hair cells of the organ of
Corti, and the stria! degeneration might manifest itself under limited conditions when exposed at relatively high concentrations of platinum compounds (Nakai et al., 1982).
On balance, however, the ototoxic effects of carboplatin in
the chinchilla are mainly on the IHC, and the effects seem
to be dependent on the peak levels of the drug rather than
the total dosage. Future studies should include correlation
of hair cell damage with drug levels and with other potential toxicities, after acute and chronic treatment.

Selective

mental animal models of various ototoxic agents to supplement data from human clinical studies. In guinea pigs
treated with carboplatin, hair cell damage occurred only
sporadically in the OHC regions, and the IHC remained intact, confirming previous observations (Schweitzer et al.,
1986; Saito et al., 1989; Tautly et al., 1992). Tautly et al.
(1992) reported that carboplatin at cumulative doses of 120
mg/kg i.p. in the guinea pig induced ABR threshold shifts
ranging from 8 to 15 dB across the frequencies, consistent
with our data. Their hair cell counts in the carboplatintreated animals also showed less than 15 % loss of the normal population and this was limited to the OHC area. On
the other hand, in our study, chinchillas, after i.p. carboplatin administration with the same dose and time schedule,
showed degenerative changes restricted to the IHC regions.
Mean IHC loss ranged from 22 to 46 % with preference toward the basal turn, while more than 98 % of OH Cs survived at all locations. Degrees of IHC damage were characterized by separation and splaying of stereocilia, bleb
formation on the plasma membrane, presence of fusion/extrusion bodies into endolymphatic space, and total loss of
IHCs. It should be noted that the morphological changes
observed here have some shared similarity with those induced by cisplatin in guinea pigs, an animal model which
has been most thoroughly studied (Comis et al., 1986;
Barron and Daigneault, 1987). Comis et al. (1986) also indicated a significant increase in calcium levels inside the
distorted hair cells during early periods after single-dose
cisplatin treatment and the onset of hair cell degeneration
closely associated with the calcium increase. Since platinum compounds are known to inactivate various plasma
membrane enzymes and, as a result, affect cellular homeostatic functions (Aggarwal and Niroomand-Rad, 1983;
Aggarwal, 1993), it has been suggested that in both animal
models changes such as the formation of blebs and fusion/
extrusion bodies may be due to the primary effect of the
drugs which directly act on hair cell metabolic mechanisms.
In addition to providing insights into the mechanisms
of drug ototoxicity, we believe that the model presented
here will allow further elucidation of cochlear mechanisms.
Just as selective OHC destruction using aminoglycosides
has revealed the contributions of hair cell groups in the
transduction process (Dallos and Wang, 1974; Evans and
Harrison, 1976; Zwislocki, 1984), the present model provides for a complementary study examining the function of
the cochlea in the absence of IHCs.

Acknowledgements
This research was supported by the Medical Research
Council Canada and the Masonic Foundation of Ontario.

References

me damage in the chinchilla

Aggarwal SK, Niroomand-Rad I (1983). Effect of cisplatin on the plasma membrane phosphatase activities in
Asites Sarcoma-180 cells: a cytochemistry study. J. Histochem. Cytochem. 31, 307-317.

Another remarkable aspect of the present study is the
distinct interspecies difference between the chinchilla and
the guinea pig. Both species are commonly used as experi-

104

Carboplatin Induced Inner Hair Cell Damage
Aggarwal SK (1993). A histochemical approach to the
mechanism of action of cisplatin and its analogues. J.
Histochem. Cytochem. 41, 1053-1073.
AnnikoM, Sobin A (1990). Cisplatin: Evaluation of its
ototoxic potential. Am. J. Otolaryngol. 7, 276-293.
Anzai T, Ohtani I, Ohtsuki K, Aikawa T, Okamura H
(1987). Ototoxicity of carboplatinand its transferability into
inner ear. Comparative study of cisplatin. Ear Res. Jpn.
18, 122-124.
Barron SE, Daigneault EA (1987). Effect of cisplatin
on hair cell morphology and lateral wall Na, K-ATPase
activity. Hear. Res. 26, 131-137.
Calvert AM, Harland S, Newell D, Siddik Z, Jones A,
McElvan R, Raju S, Whiltshaw E, Smith D, Baker J,
Peckham M, Harrop K (1982). Early clinical studies with
Cis-diammine-1. 1-cyclobutane dicarboxylate platinum IL
Cancer Chemother. Pharmacol. 9, 140-147.
Comis SD, Rhys-Evans PH, Osborne MP, Pickles JO,
Jeffries DJR, Pearse HAC (1986). Early morphological and
chemical changes induced by cisplatin in the guinea pig
organ of Corti. J. Laryngol. Otol. 100, 1375-1383.
Dallos P, Wang CY (1974). Bioelectric correlates of
kanamycin intoxication. Audiology 13, 277-289.
Eldredge DH, Miller D, Bohne BA (1981). A frequency-position map for the chinchilla cochlea. J. Acoust. Soc.
Am. 69, 1091-1095.
Estrem SA, Babin RW, Ryu JH, Moore KC (1981).
Cis-diamminedichloroplatinum(II) ototoxicity in the guinea
pig. Otolaryngol. Head Neck Surg. 89, 638-645.
Evans EF, Harrison RV (1976). Correlation between
outer hair cell damage and deterioration of cochlear nerve
tuning properties in the guinea pig. J. Physiol. 256, 43-44.
FukushimaN, White P, Harrison RV (1990). Influence
of acoustic deprivation on recovery of hair cells after
acoustic trauma. Hear. Res. 50, 107-118.
Gratton MA, Salvi RJ, Kamen BA, Saunders SS
(1990). Interaction of cisplatin and noise on the peripheral
auditory system. Hear. Res. 50, 211-224.
Jones RB, Myers CE, Guarino AM, Dedrick RL,
Hubbard SM, De Vita VT (1978). High volume intraperitoneal chemotherapy ("Belly Bath") for ovarian cancer.
Cancer Chemother. Pharmacol. 1, 161-166.
Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH
(1990). Carboplatin is ototoxic. Cancer Chemother.
Pharmacol. 26, 232-234.
Kohn S, Fradis M, Pratt H, Zidan J, Podoshin L,
Robinson E, Nir I (1988). Cisplatin ototoxicity in guinea
pigs with special reference to toxic effects in the stria
vascularis. Laryngoscope 98, 865-871.
Kohn S, Fradis M, Podoshin L, David YB, Zidan J,
Robinson E, Nir I (1991). Toxic effects of cisplatin alone
and in combination with gentamicin in stria vascularis of
guinea pigs. Laryngoscope 101, 709-716.
Konishi T, Gupta BN, PrazmaJ (1983). Ototoxicity of
cis-dichlorodiamine platinum (II) in guinea pigs. Am. J.
Otolaryngol. 4, 18-26.
Kopelman J, Budnick AS, Sessions RB, Kramer MB,

Wong GY (1988). Ototoxicity of high-dose cisplatin in
patients with advanced cancers and normal hearing.
Laryngoscope 98, 858-864.
Laurell G, Engstrom B (1989). The ototoxic effect of
cisplatin on guinea pigs in relation to dosage. Hear. Res.
38, 27-34.
Lippman A, Helson C, Helson L, Krakoff H (1973).
Clinical trials of cis-diamminedichloroplatinum (NSC119875). Cancer Chemother. Rep. 57, 191-200.
Litterst CL, Gram TE, Dedrick RL, Leroy AF,
Guarino AM (1976). Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum (II) (NSC 119875) to dogs. Cancer Res.
36, 2340-2344.
Macdonald MR, Harrison RV, Wake M, Bliss B,
Macdonald RE (1994). Ototoxicity of carboplatin: Comparing animal and clinical models at the Hospital for Sick
Children. J. Otolaryngol. 23, 151-159.
Marco-Algarra J, Basterra J, Marco J (1985). Cisdiaminedichloro platinum ototoxicity. An experimental
study. Acta Otolaryngol. (Stockh.) 99, 343-347.
McAlpine D, Johnstone BM (1990). The ototoxic
mechanism of cisplatin. Hear. Res. 47, 191-204.
Myers SF, Blakley BW, Schwan S, Rintelmann WA,
Mathog RH (1991). The "plateau effect" of cis-platinuminduced hearing Joss. Otolaryngol. Head Neck Surg. 104,
122-127.
Nakai Y, Konishi K, Chang KC, Ohashi K, Morisaki
N, Minowa Y, Morimoto A (1982). Ototoxicity of the anticancer drug cisplatin. Acta. Otolaryngol. (Stockh.) 93, 227232.
Piel U, Meyer D, Perlia CP, Wolfe VI (1974). Effects
of cis-diamminedichloroplatinum (NSC-119875) on hearing
function in man. Cancer Chemother. Rep. 58, 871-875.
Pretorius RG, Petrilli ES, Kean C, Ford LC,
Hoeschele JD, Lagasse LD (1981). Comparison of the iv
and ip routes of administration of cisplatin in dogs. Cancer
Treatment Reports 65, 1055-1062.
Rosenberg B, Van Camp L, Krigas T (1965). Inhibition of cell division in Escherichia coli by electrolysis
products from a platinum electrode. Nature 205, 698-699.
Rosenberg B, Van Camp L, Trosko JE, Mansoum VH
(1969). Platinum compounds: a new class of potent antitumor agents. Nature 222, 385-386.
Saito T, Saito H, Saito K, Wakui S, Manabe Y, Tsuda
G (1989). Ototoxicity of carboplatin in guinea pigs. Auris
Nasus Larynx 16, 13-21.
Schweitzer VG, Hawkins JE, Lilly DJ, Litterst CJ,
Abrams G, Davis JA, Christy M (1984). Ototoxic and
nephrotoxic effects of combined treatment with cisdiamminedichloroplatinum and kanamycin in the guinea
pig. Otolarygol. Head Neck Surg. 92, 38-49.
Schweitzer VG,. Rarey KE, Dolan DF, Abrams G,
Litterst CJ, Sheridan C (1986). Ototoxicity of cisplatin vs.
platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol. Head Neck Surg. 94, 458-470.
Stadnicki SW, Fleischmann RW, Schaeppi U, Merriam
105

S. Takeno, R.V. Harrison, R.J. Mount, M. Wake, Y. Harada
P (1975). Cis-dichlorodiammineplatinurr(II) (NSC-119875):
Hearing loss and other toxic effects in rhesus monkeys.
Cancer Chemother. Rep. 59, 467-480.
Strauss M, Towfighi J, Lipton A, Brown B, Lord S,
Harvey H (1983). Cisplatinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope 93,
1554-1559.
Takeno S, Harrison RV, Ibrahim D, Wake M, Mount
RJ (1994). Cochlear function after selective inner hair cell
degenerationinduced by carboplatin.Hear. Res. 75, 93-102.
TangeRA, ConijnEAJG, vanZeijlLGPM(1982). The
cortitoxic effects of cis-platinum in the guinea pig. Arch.
Otorhinolaryngol. 237: 17-26.
Tange RA, Vuzevski VD (1984). Changes in the stria
vascularis of the guinea pig due to cis-platinum. Arch.
Otorhinolaryngol. 239: 41-47.
Tautly M, Syka J, Popelar J, Ulehlova L (1992).
Carboplatin and cisplatin ototoxicity in guinea pigs.
Audiology 31, 293-299.
van Hennik MB, van der Vijgh WJF, Klein I, Elferink
F, VermorkenJB, Winograd B, Pinedo HM (1987). Comparative pharmacokinetics of cisplatin and three analogues
in mice and humans. Cancer Res. 47: 6297-6301.
Wake M, Takeno S, Ibrahim D, Harrison RV, Mount
RJ (1993). Carboplatin ototoxicity, an animal model. J.
Laryngol. Oto!. 107: 585-589.
Wright CG, Schaefer SD (1982). Inner ear histopathology in patients treated with cis-platinum. Laryngoscope 92:
1408-1413.
Yates FE, Kugler PN (1986). Similarity principles and
intrinsic geometries: Contrasting approaches to interspecies
scaling. J. Pharm. Sci. 75: 1019-1027.
Zwislocki J (1984). How OHC lesions can lead to neural cochlear hypersensitivity. Acta Otolaryngol. (Stockh.)
97: 529-534.

ciated nerve endings, both at acute and chronic stages. The
results will be reported in the near future.

Y. Nakai: Do the authors have any idea why IHCs in the
chinchilla are more vulnerable than OHCs to carboplatin?
S.K. Aggarwal: Do the authors expect the mechanism for
hair cell damage after carboplatin to be the same as after
cisplatin treatment, i.e., through intracellular calcium
changes?
G. Laurell: The present study describes species differences
between the chinchilla and the guinea pig. Can the selective
IHC damage in the chinchilla be explained by a specific
drug distribution inside the cochlea or can it be explained by
cellular mechanism of carboplatin ototoxicity at the IHC
level?
V.G. Schweitzer: It would be interesting to compare the
toxicities in the chinchilla model of carboplatin versus cisplatin including: morphological and electrophysiological
function of OHCs and IHCs; serum drug levels after acute
dosing; and other types of toxicities manifested (nephrotoxicity, neurotoxicity, bone marrow suppression, GI
toxicity, as well as ototoxicity).
Authors: We do not have any direct evidence to postulate
on the mechanism of selective THC damage in the chinchilla. However, we would like to draw attention to the fact
that cisplatin in the chinchilla does cause the usual OHC
damage (Gratton et al., 1990; our preliminary data). The
effect of cisplatin on the chinchilla cochlea is similar to its
effect on the guinea pig as reported by Comis et al. (1986);
they noted significant increases in calcium levels in abnormal outer hair cells of the guinea pig cochlea. It is possible
to speculate that the difference in molecular structure between carboplatinand cisplatin causes discriminativeaffinity
for the two types of cochlea hair cells in the chinchilla. The
combination of these two toxic effects in the same species
are amazing and worth further investigation since they may
enable us to elicit the key mechanism of platinum ototoxicity.

Discussion with Reviewers

S.D. Comis: Do the authors have any data regarding the
possible long term (many months) effects of carboplatin on
OHCs?
Authors: We are maintaining a small colony of carboplatin
treated chinchillas to investigate long term effects of the
drug. Preliminary data has shown that the selective IHC
damage can be maintained with complete OHC preservation
at least six months. Results of this chronic study will be
reported in the future.

Y. Nakai: Are there any special degenerative features in
the inner hair cell cytoplasm, nerve endings or fibers associated with the ototoxic effects of carboplatin?
S.D. Comis: Are the authors planning to confirm by transmission electron microscopy (TEM) that there are no untoward changes in the morphology of the OHC synapse-nerve
fiber unit after carboplatin administration? It would be
interesting to know if there are any degenerative changes in
the nerve fibers associated with the IHCs.
Authors: Our previous study (Wake et al., 1993) demonstrated abnormal IHC stereocilia with evidence of fusion/
extrusion bodies by light microscopy (LM) observations.
OHC stereocilia and cell bodies appeared normal at the LM
level. In addition, the spiral ganglion showed scattered
Type I cell degenerative changes with pyknosis or nuclear
disruption. Those features were observed two weeks after
a single i.v. treatment of 400 mg/m 2 carboplatin. We are
currently preparing specimens for TEM to investigate the
ultrastructure of selectively damaged IHCs and their asso-

S.D. Comis: Have any studies been performed on these
chinchillas to look for changes in otoacoustic emissions?
V.G. Schweitzer: Do the authors consider the use of additional modalities to evaluate inner hair cell function, such as
single unit hair cell recording and evaluation of the IHCs on
a subcellular level?
Authors: We agree that studies of both single unit hair cell
recording and otoacoustic emissions using this animal model
would be of great value. The project is currently m
progress and results will be reported in the future.
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